This article has some of the latest longevity developments for those interested.
I wanted to highlight this section on Alzheimer’s research and the role of amyloid. We’ve discussed this before in the blog , and the huge controversy about the approval of the drug Aduhelm in newsletters. This article discusses a new drug that targets amyloid and showed slight improvment.
But the question, to me, is one of opportunity costs. The more they chase the amyloid question, the fewer resources are left for other avenues of intervention, for example neuroinflammation. For those who have read my book, you might have come to appreciate the outsized role that inflammation plays in all aspects of health and aging.
